Menu
Search
|

Menu

Close
X

Apellis Pharmaceuticals Inc APLS.OQ (NASDAQ Stock Exchange Global Select Market)

26.25 USD
-- (--)
As of Sep 18
Previous Close 26.25
Open --
Volume --
3m Avg Volume 148,126
Today’s High --
Today’s Low --
52 Week High 33.18
52 Week Low 11.45
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.62 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-1.997
FY18
-2.329
FY17
-1.036
FY16
-0.281
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
--
7.91
Price to Book (MRQ)
vs sector
--
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
--
14.55
LT Debt to Equity (MRQ)
vs sector
--
10.20
Return on Investment (TTM)
vs sector
--
14.48
Return on Equity (TTM)
vs sector
--
15.78

EXECUTIVE LEADERSHIP

Gerald Chan
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Cedric Francois
President, Chief Executive Officer, Co-Founder, Director, Since 2016
Salary: $550,000.00
Bonus: $381,562.00
Pascal Deschatelets
Co-Founder, Chief Operating Officer, Since 2016
Salary: $400,000.00
Bonus: $225,000.00
Timothy Sullivan
Chief Financial Officer, Treasurer, Since 2017
Salary: $380,000.00
Bonus: $190,000.00
Thomas Lackner
Senior Vice President, Head of Europe, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

6400 Westwind Way Ste a
CRESTWOOD   KY   40014-6773

Phone: +1502.2414114
Site: apellis.com/

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.

SPONSORED STORIES